NoticeThis is an independent non-profit initiative. We are not affiliated with the European Medicines Agency (EMA) or the official CTIS system. For the official EU Clinical Trials Information System, visit:
EMA Registry →
Patients with localised prostate cancer and high-risk features of relapse (minimum 2 high-risk criteria from National Comprehensive Cancer Network (NCCN) classification)1 and with no detectable metastasis, including no evidence of pelvic lymph node metastasis on next-generation imaging (PSMA PET/CT).
1 total trials1 recruiting
Filter these 1 trials by phase, country, sponsor and more.